Pubblicazioni
Le nostre ultime pubblicazioni.
Most recent publications
Milazzo FM, Chaves-Sanjuan A, Minenkova O, Santapaola D, Anastasi AM, Battistuzzi G, Chiapparino C, Rosi A, Merlo Pich E, Albertoni C, Marra E, Luberto L, Viollet C, Spagnoli LG, Riccio A, Rossi A, Santoro G, Ballabio F, Paissoni C, Camilloni C, Bolognesi M, De Santis R. Spike mutation resilient scFv76 antibody counteracts SARS-CoV-2 lung damage upon aerosol delivery. Mol Ther, 31(2):362-373, 2023 https://doi.org/10.1016/j.ymthe.2022.09.01
Minenkova O, Santapaola D,Milazzo FM, Anastasi AM, Battistuzzi G, Chiapparino C, Rosi A, Gritti G, Borleri G, Rambaldi A, Dental C, Viollet C, Pagano B, Salvini L, Marra E, Luberto L, Rossi A, Riccio A, Merlo Pich E, Santoro MG, De Santis R. Human inhalable antibody fragments neutralizing SARS-CoV-2 variants for COVID-19 therapy. Mol Ther. 30(5):1-15, 2022 https://doi.org/10.1016/j.ymthe.2022.02.013
Cianferotti C, Faltoni V, Cini E, Elena Ermini E, Migliorini F, Petricci E, Taddei M, Salvini L, Battistuzzi G, Milazzo FM, Anastasi AM, Chiapparino C, De Santis R and Giannini G. Antibody drug conjugates with hydroxamic acid cargos for histone deacetylase (HDAC) inhibition. Chem Commun, 57, 867-870, 2021 https://doi.org/10.1039/d0cc06131j
De Santis R. Anti-ErbB2 immunotherapeutics: Struggling to make better antibodies for cancer therapy. Mabs, 12(1):e1725346, 2020 https://www.ncbi.nlm.nih.gov/pubmed/32054397
Milazzo FM, Vesci L, Anastasi AM, Chiapparino C, Rosi A, Giannini G, Taddei M, Cini E, Faltoni V, Petricci E, Battistuzzi G, Salvini L, Carollo V, De Santis R. ErbB2 targeted epigenetic modulation: anti-tumor efficacy of the ADC trastuzumab-HDACi ST8176AA1. Front Oncol. 9:1534, 2020. doi: 10.3389/fonc.2019.01534 https://www.ncbi.nlm.nih.gov/pubmed/32039017
Publications on AvidinOX
Vesci L, Carollo V, Rosi A, De Santis R. Therapeutic efficacy of intra-tumor AvidinOX and low systemic dose biotinylated Cetuximab with and without Cisplatin in an orthotopic model of head and neck cancer. Oncol Lett 17(3):3529-3536, 2019 https://www.ncbi.nlm.nih.gov/pubmed/30867794
Minenkova O, Vesci L, De Santis R, Santapaola D, Cincinelli R, Musso L, Dallavalle S Giannini G. Growth inhibition of human ovarian carcinoma by a novel AvidinOX-anchored biotinylated camptothecin derivative. Bioorg Med Chem Letters,28(20):3312-3314, 2018 https://www.ncbi.nlm.nih.gov/pubmed/30243588
Giannini G, Alekseeva A, Naggi A, Salvini L, Tei L, De Santis R. Characterization of therapeutic protein AvidinOX by an integrated analytical approach. Anal Bioanal Chem 410(2):553-564, 2018 https://www.ncbi.nlm.nih.gov/pubmed/29167933
Milazzo FM, Anastasi AM, Chiapparino C, Rosi A, Leoni B, Vesci L, Petronzelli F, and De Santis R. AvidinOX-anchored biotinylated Trastuzumab and Pertuzumab induce down-modulation of ErbB2 and tumor cell death at concentrations order of magnitude lower than not-anchored antibodies. Oncotarget 8(14):22590-22605, 2017 https://www.ncbi.nlm.nih.gov/pubmed/28186982
Vesci L, Milazzo FM, Anastasi AM, Chiapparino C, Carollo V, Roscilli G, Marra E, Luberto L, Aurisicchio L, Spagnoli LG and De Santis R. Intra-tumor AvidinOX allows efficacy of low dose systemic biotinylated Cetuximab in a model of tongue cancer. Oncotarget 7(1):914-928, 2016 http://www.ncbi.nlm.nih.gov/pubmed/26575422
Albertoni C, Leoni B, Rosi A, D’Alessio V, Carollo V, Spagnoli LG, vanEtcheld C, De Santis R. Radionuclide therapy of unresectable tumors with AvidinOX and 90Y-biotinDOTA: tongue cancer paradigm. Cancer Biother Radiopharmaceuticals 30(7):291-298, 2015 http://www.ncbi.nlm.nih.gov/pubmed/26167947
De Santis R, Rosi A, Anastasi AM, Chiapparino C, Albertoni C, Leoni B, Pelliccia A, Santapaola D, Carollo V, Marra E, Aurisicchio L, Arseni B, Pacello ML, Palmieri G, Battella S, Petronzelli F, Milazzo FM. Efficacy of aerosol therapy of lung cancer correlates with EGFR paralysis induced by AvidinOX-anchored biotinylated Cetuximab. Oncotarget 5(19):9239-9255, 2014 http://www.ncbi.nlm.nih.gov/pubmed/25238453
Nucera E, Nicoletti C, Chiapparino C, Pacello ML, D’Alessio V, Musarò A, and De Santis R. AvidinOX for tissue targeted delivery of biotinylated cells. Int J Immunopathol Pharmacol 25(1): 239-246, 2012 http://www.ncbi.nlm.nih.gov/pubmed/22507336
De Santis R, Anastasi AM, Pelliccia A, Rosi A, Albertoni C, Verdoliva A, Petronzelli F, D’Alessio V, Serani S, Nuzzolo CA. Chemical linkage to injected tissues is a distinctive property of oxidized avidin. PLoS One 6(6):e21075,2011 http://www.ncbi.nlm.nih.gov/pubmed/21701578
Petronzelli F, Anastasi AM, Pelliccia A, Santapaola D, Albertoni C, Rosi A, Leoni B, Ferrari L, Paganelli G, Gramiccioli G, Pesce D, Alfano AM, Stasi M A and De Santis R. Preclinical pharmacology and safety of a novel avidin derivative for tissue-targeted delivery of radiolabeled biotin. Basic Clin Pharmacol Toxicol 109(3):145-155, 2011 http://www.ncbi.nlm.nih.gov/pubmed/21426491
Petronzelli F, Pelliccia A, Anastasi AM, Lindstedt RF, Manganello S, Ferrari L, Albertoni C, Leoni B, Rosi A, D’Alessio V, Deiana K, Carminati P, Paganelli G, De Santis R. Therapeutic use of avidin is not hampered by anti-avidin antibodies in humans. Cancer Biother Radiopharmaceuticals 25(5): 563-570, 2010 http://www.ncbi.nlm.nih.gov/pubmed/20863248
De Santis R, Leoni B, Rosi A, Albertoni C, Forni G, Cojoca R, Iezzi M, Musiani P, Paganelli G, Chinol M, Carminati P. AvidinOX™ for highly efficient tissue pre-targeted radionuclide therapy. Cancer Biother Radiopharmaceuticals 25(2):143-148, 2010 http://www.ncbi.nlm.nih.gov/pubmed/20423226
Verdoliva A, Bellofiore P, Rivieccio V, Catello S, Colombo M, Albertoni C, Rosi A, Leoni B, Anastasi AM, De Santis R. Biochemical and biological characterization of a new oxidized avidin with enhanced tissue binding properties. J Biol Chem 286(12):9090-9099, 2010 http://www.ncbi.nlm.nih.gov/pubmed/20100839
De Santis R, Albertoni C, Rosi A, Leoni B, Petronzelli F, D’Alessio V, Nucera E, Salvatori G, Paganelli G, Carminati P, Nuzzolo CA. OXavidin for tissue targeting biotinylated therapeutics. J Biomed Biotechnol doi:10.1155/2009/921434, 2010 http://www.ncbi.nlm.nih.gov/pubmed/20130784
ISCRIVITI ALLA NEWSLETTER
Resta in contatto con noi.
Sede Legale
Kiran biotech S.r.l. Viale Dei Santi Pietro e Paolo, 50 00144 Roma - Laboratori operativi: facoltà di medicina presso Università degli studi di Tor Vergata, Roma
Chiamaci
+39 334 681 7267